Hamza Hafiz Muhammad, Tariq Muhammad Daoud, Ahsan Areeba, Sarfraz Tariq, Malik Muhammad Muiz, Aneeqa Saba, Awan Ayaz Ahmed, Rai Deepak, Iftikhar Haissan
Department of General Surgery, Foundation University Medical College, Islamabad, Pakistan.
Department of Internal Medicine, Foundation University Medical College, Islamabad, Pakistan.
Ann Med Surg (Lond). 2025 Jun 10;87(8):4853-4860. doi: 10.1097/MS9.0000000000003470. eCollection 2025 Aug.
Breast cancer accounts for 24.5% of all cancer cases in women globally, with over 670 000 deaths annually. Early detection and accurate diagnosis are crucial, with breast biopsy reports being key to diagnosis and prognosis. This audit assessed the quality of breast biopsy reports to improve adherence to standardized reporting.
A two-cycle clinical audit was conducted at Fauji Foundation Hospital. The first cycle (January 1-March 1, 2024) reviewed 200 biopsy reports against the Royal College of Pathologists' minimum dataset. Identified deficiencies led to an educational intervention, including targeted training and a standardized reporting template. The second cycle (May 16-July 10, 2024) evaluated the intervention's impact.
The first cycle showed high compliance in documenting patient profiles and certain pathological findings, but revealed notable gaps in reporting hormone receptor status (estrogen receptor [ER] and progesterone receptor [PR]) and Human Epidermal growth factor Receptor 2 (HER2) metrics (67.1% compliance). Following the educational intervention and implementation of a standardized template, compliance for these metrics improved to 80.2%. Additional improvements were observed in the use of B category classification, histological typing, and overall adherence to the Royal College of Pathologists' minimum dataset.
The intervention significantly improved the quality of breast biopsy reports, particularly in the documentation of hormone receptor status and HER2 metrics. Sustained training, periodic audits, and continued use of standardized templates are recommended to maintain and further enhance reporting standards.
乳腺癌占全球女性所有癌症病例的24.5%,每年有超过67万例死亡。早期检测和准确诊断至关重要,乳腺活检报告是诊断和预后的关键。本次审核评估了乳腺活检报告的质量,以提高对标准化报告的依从性。
在法吉基金会医院进行了一个两阶段的临床审核。第一阶段(2024年1月1日至3月1日)对照皇家病理学家学院的最小数据集审查了200份活检报告。发现的缺陷导致了教育干预,包括针对性培训和标准化报告模板。第二阶段(2024年5月16日至7月10日)评估了干预的影响。
第一阶段显示在记录患者资料和某些病理结果方面有较高的依从性,但在报告激素受体状态(雌激素受体[ER]和孕激素受体[PR])和人表皮生长因子受体2(HER2)指标方面存在明显差距(依从率为67.1%)。在进行教育干预并实施标准化模板后,这些指标的依从率提高到了80.2%。在使用B类分类、组织学类型以及对皇家病理学家学院最小数据集的总体依从性方面也观察到了进一步的改善。
该干预显著提高了乳腺活检报告的质量,特别是在激素受体状态和HER2指标的记录方面。建议持续培训、定期审核并持续使用标准化模板,以维持并进一步提高报告标准。